Ortho/Stratagene MAb technology
Executive Summary
Two firms have rights to new E. coli-based monoclonal antibody technology developed at the Research Institute of the Scripps Clinic which potentially offers greater speed, variety and economy than the current mouse or human-based production media. Ortho parent J&J has the rights to license healthcare-related technologies developed by Scripps. The privately-held molecular biology products supplier Stratagene, has set up a new company, Stratacyte, to exploit and license the technology to the research community.